FDA offers guidance for generic drug developers of hydroxychloroquine, chloroquine
The FDA on Monday issued two new product-specific guidance documents for the unproven but highly demanded potential Covid-19 drugs chloroquine phosphate and hydroxychloroquine sulfate.
The two generic drugs, approved by FDA as malaria drugs, have been touted by President Donald Trump in press conferences during the pandemic, but clinical trial data regarding their efficacy for COVID-19 remain thin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.